Identifying patients at risk: multi-centre comparison of HeartMate 3 and HeartWare left ventricular assist devices.
Lieke NumanDaniel ZimpferOsnat Itzhaki Ben ZadokEmmeke AartsMichiel MorshuisSabina P W GuentherJulia RiebandtDominik WiedemannFaiz Z RamjankhanAnne-Marie OppelaarTuvia Ben-GalBinyamin Ben-AvrahamFolkert W. AsselbergsRene SchrammLinda W Van LaakePublished in: ESC heart failure (2023)
HM3 patients have a significantly better survival and a lower incidence of ischaemic strokes and pump thrombosis than HVAD patients. This survival difference persisted after 2 years of implantation. Additional research using post-operative variables is warranted to identify which HVAD patients need an upgrade to HM3 or expedited transplantation.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- left ventricular
- peritoneal dialysis
- prognostic factors
- stem cells
- pulmonary embolism
- risk factors
- bone marrow
- acute coronary syndrome
- percutaneous coronary intervention
- transcatheter aortic valve replacement
- left ventricular assist device
- cardiac resynchronization therapy